Publication | Open Access
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
36
Citations
10
References
2020
Year
Unknown Venue
Acute Lung InjuryImmunodeficienciesImmunologyCovid-19 EpidemiologyImmune SystemCytokine ProfileCovid-19InflammationElevated LevelsInflammatory MarkerSepsisSepsis PhenotypingInflammatory CytokinesCovid-19 PandemicSevere Covid-19Chronic InflammationHumoral ImmunitySepsis PatientsChronic Viral InfectionInflammatory DiseaseCytokineInflammation BiologyMedicine
Rationale: Elevated levels of inflammatory cytokines have been associated with poor outcomes among COVID-19 patients. It is unknown, however, how these levels compare to those observed in critically ill patients with ARDS or sepsis due to other causes. Objectives: To directly compare plasma levels of inflammatory cytokines, with a focus on 6 cytokines associated with cytokine storm (IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα), between hospitalized COVID-19 patients and banked plasma samples from ARDS and sepsis patients from prior to the COVID-19 pandemic. Findings: 15 hospitalized COVID-19 patients, 9 of whom were critically ill, were compared to 28 critically ill patients with ARDS or sepsis. There were no statistically significant differences in baseline levels of IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα between patients with severe COVID-19 and critically ill controls with ARDS or sepsis. Conclusions: Levels of inflammatory cytokines IL-1b, IL-1RA, IL-6, IL-8, IL-18, and TNFα were not higher in critically ill COVID-19 patients than in critically ill patients admitted with ARDS or sepsis due to other causes in this small cohort. Broad use of immunosuppressive therapies in ARDS has failed in numerous Phase 3 studies; use of these therapies in unselected patients with COVID-19 is likely unwarranted.
| Year | Citations | |
|---|---|---|
2020 | 28.8K | |
2020 | 5.1K | |
2020 | 5K | |
1995 | 798 | |
2014 | 746 | |
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial Carolyn S. Calfee, Kevin Delucchi, Pratik Sinha, The Lancet Respiratory Medicine Acute Lung InjuryCardiovascular DiseaseRespiratory Distress Syndrome (Pulmonary Critical Care)Acute CareInflammatory Marker | 2018 | 716 |
2018 | 349 | |
2016 | 124 | |
2020 | 120 | |
2020 | 17 |
Page 1
Page 1